In the article by Chen Z. et al. published in the Lancet (2025; 406: 2078–88), the appendix has been replaced and the authors' affiliations updated.[user content] These corrections were made in the online version on 15 January 2026.[user content] The HARMONi-6 study is a randomized, double-blind, phase 3 study comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy as first-line treatment lines of advanced squamous non-small cell lung cancer.[user content][1][2] Ivonescimab is a bispecific antibody targeting PD-L1 and VEGF.[2] The study demonstrated statistically significant superiority of ivonescimab plus chemotherapy in progression-free progression with an HR of 0.60 (95% CI 0.46–0.78).[1] Adverse events were manageable.[1] Data on overall survival are still immature.[1]